Autor según el artículo: Zamora A, Masana L, Comas-Cufí M, Vila À, Plana N, García-Gil M, Alves-Cabratosa L, Marrugat J, Roman I, Ramos R, XULA and ISV-Girona groups
Departamento: Medicina i Cirurgia
Autor/es de la URV: Masana Marín, Luis / Plana Gil, Núria
Palabras clave: Paper Panel Goals Familial hypercholesterolemia Electronic health records Disease Diagnosis Children Cardiovascular disease electronic health records cardiovascular disease
Resumen: Background Familial hypercholesterolemia (FH), the most frequent hereditary cause of premature coronary heart disease (CHD), is underdiagnosed and insufficiently treated. Objectives The objectives of the study were to estimate the prevalence of the FH phenotype (FH-P) and to describe its clinical characteristics in a Mediterranean population. Methods Data were obtained from the Catalan primary care system's clinical records database (Catalan acronym: SIDIAP). Patients aged >7 years with at least 1 low-density lipoprotein cholesterol measurement recorded between 2006 and 2014 (n = 2,554,644) were included. Heterozygous FH-P and homozygous FH-P were defined by untreated low-density lipoprotein cholesterol plasma concentrations. The presence of cardiovascular diseases and risk factors was defined by coded medical records from primary care and hospital discharge databases. Results The age- and sex-standardized prevalence of heterozygous FH-P and homozygous FH-P were 1/192 individuals and 1/425,774 individuals, respectively. In the group aged 8 to 18 years, 0.46% (95% confidence interval: 0.41-0.52) had FH-P; overall prevalence was 0.58% (95% confidence interval: 0.58-0.60). Among patients with FH-P aged >18 years, cardiovascular disease prevalence was 3.5 times higher than in general population, and CHD prevalence in those aged 35 to 59 years was 4.5 times higher than in those without FH-P. Lipid-lowering therapy was lacking in 13.5% of patients with FH-P, and only 31.6% of men and 22.7 of women were receiving high or very high-intensity lipid-lowering therapy. Conclusion Prevalence of FH-P was higher than expected, but underdiagnosed and suboptimally treated, especially in women. Moreover, treatment started late considering the high CHD incidence associated with this condition.
Áreas temáticas: Saúde coletiva Pharmacology & pharmacy Nutrition and dietetics Nutrição Medicina ii Medicina i Internal medicine Interdisciplinar Farmacia Endocrinology, diabetes and metabolism Educação física Ciências biológicas ii Cardiology and cardiovascular medicine
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 19332874
Direcció de correo del autor: luis.masana@urv.cat
Identificador del autor: 0000-0002-0789-4954
Fecha de alta del registro: 2024-09-07
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://www.lipidjournal.com/article/S1933-2874(17)30338-0/fulltext
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Journal Of Clinical Lipidology. 11 (4): 1013-1022
Referencia de l'ítem segons les normes APA: Zamora A, Masana L, Comas-Cufí M, Vila À, Plana N, García-Gil M, Alves-Cabratosa L, Marrugat J, Roman I, Ramos R, XULA and ISV-Girona groups (2017). Familial hypercholesterolemia in a European Mediterranean population -Prevalence and clinical data from 2.5 milion primary care patients.. Journal Of Clinical Lipidology, 11(4), 1013-1022. DOI: 10.1016/j.jacl.2017.05.012
DOI del artículo: 10.1016/j.jacl.2017.05.012
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2017
Tipo de publicación: Journal Publications
Repositori URV